Mistargeted T-cell activity can lead to episodic inflammatory reactions, which are a characteristic of autoimmune diseases, thus prevention of these cascades is an important therapeutic goal. Common immunosuppressants or cortisone do not act at the origin of the disease and therefore cannot stop its progression. Based on in vitro experiments with human peripheral blood cells from voluntary donors, so-called T-cell silencers could be identified. These may have the potential to prevent diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis directly at its origin, at the unwanted T cell activity.
Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!